Fig. 2.

ST6GALNAC1 is highly expressed in OCSCs and ovarian cancer cells. a Relative expression of ST6GALNAC1 in ovarian cancer (n = 48; data were compared using paired t-test; *p < 0.05 vs. the normal tissues); b relative expression of ST6GALNAC1 in ovarian cancer cell line and ovarian cell line (*p < 0.05 vs. IOSE80); c relative expression of ST6GALNAC1 in non-spheroids and spheroids (*p < 0.05 vs. non-spheroids); d relative expression of ST6GALNAC1 in CD90⁺ and CD90⁻ (*p < 0.05 vs. CD90⁻); e RT-qPCR of CD44, Nanog, and Oct4 (*p < 0.05 vs. IOSE80); f Western blot analysis of CD44, Nanog, and Oct4; g tumorsphere formation number (*p < 0.05 vs. IOSE80); h the tumorsphere formation 10 days after culture. The measurement data were expressed as mean ± standard deviation. The test between two groups was analyzed by t-test, and the one-way ANOVA was used for analysis among the multiple groups. The experiment was repeated 3 times